Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 01 Jul 2019
At a glance
- Drugs Dexamethasone (Primary) ; Oprozomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 27 Jun 2019 Status changed from active, no longer recruiting to completed.
- 11 Feb 2019 Planned End Date changed from 28 Feb 2019 to 30 Jun 2019.
- 11 Feb 2019 Planned primary completion date changed from 28 Feb 2019 to 30 Jun 2019.